The company also issued a 2025 guidance that fell short of expectations, as some of the company’s older drugs face competition from cheaper generics.
Related Posts
Why U.S. tech companies struggle to replicate China’s WeChat ‘super app’ model
While ‘super apps’ have flourished in Asia, their adoption in Western markets has been slower. But more tech companies seek to bring the same model […]
Trump slams Supreme Court, Springsteen and Swift
The posts showed Trump retraining his focus on a range of domestic issues and grievances after his whirlwind tour of the Middle East.
House Republicans hit the brakes on town halls after blowback over Trump’s cuts
A number of Republican lawmakers faced significant pushback in their home districts over Trump and Elon Musk’s slashing of the federal government.